Trial Profile

A Phase II, Open-Label Trial of PT-112 in Subjects With Thymoma and Thymic Carcinoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imifoplatin (Primary)
Indications Malignant thymoma; Thymic epithelial tumour; Thymoma
Focus Proof of concept; Therapeutic Use

Most Recent Events

22 Dec 2025 According to Promontory Therapeutics media release, after reaching the interim efficacy requirement, enrollment of patients with recurrent thymoma continues at the National Cancer Institute (NCI), the single site leading the Phase 2 study of PT-112 under a formal Collaborative Research and Development Agreement (CRADA) with Promontory Therapeutics.
22 Dec 2025 Interim results published in the Media Release
16 Jul 2025 Planned End Date changed from 30 Jun 2025 to 30 Jun 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com